Hasil Pencarian - Paula Rodriguez Otero

Perbaiki Hasil
  1. 1
    CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?

    CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy? oleh Paula Rodriguez-Otero, Thomas Martin

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results

    Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results oleh Marc S. Raab, Elena Zamagni, Salomon Manier, Paula Rodriguez‐Otero, Fredrik Schjesvold, Annemiek Broijl

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Is immunotherapy here to stay in multiple myeloma?

    Is immunotherapy here to stay in multiple myeloma? oleh Paula Rodríguez-Otero, Bruno Paiva, Monika Engelhardt, Felipe Prósper, Jesús F. San Miguel

    Diterbitkan 2017-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)

    P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM... oleh Bruno Paiva, Anastasiia Zherniakova, Jorge Nuñez, Paula Rodríguez-Otero, Qian Shi, Nikhil Munshi, Brian Durie, Jesús San Miguel

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Single-Institution Experience in Clinical Trials During the COVID-19 Pandemic in Spain: Not So Bad After All?

    Single-Institution Experience in Clinical Trials During the COVID-19 Pandemic in Spain: Not So Bad After All? oleh Paula Rodriguez-Otero, Joana Reis, Ana Alfonso-Pierola, Diego Salas-Benito, Miriam Giraldez, Jose Ramón Azanza, Mariano Ponz-Sarvise

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

    CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil oleh Vania Hungria, Ana Alfonso Piérola, Jayr Schmidt Filho, Edvan Crusoe, Roberto José Pessoa de Magalhães Filho, Angelo Maiolino, Paula Rodríguez-Otero

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A

    P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A oleh Katja Weisel, Nizar J Bahlis, Paula Rodríguez-Otero, Andrea Viqueira, Shen-Wu Wang, Sangeetha Sathiah, Douglas Robinson, Thomas O’brien, Hang Quach

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A

    P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A oleh Paula Rodríguez-Otero, Hang Quach, Katja Weisel, Andrea Viqueira, Shen-Wu Wang, Phineas T. Hamilton, Tao Xie, Thomas O’brien, Nizar J Bahlis

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

    Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity oleh Nicolas Martinez-Calle, Paula Rodriguez-Otero, Sara Villar, Luis Mejías, Ignacio Melero, Felipe Prosper, Patricia Marinello, Bruno Paiva, Miguel Idoate, Jesus San-Miguel

    Diterbitkan 2018-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB

    P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB oleh Maria-Victoria Mateos, Nizar J Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodríguez-Otero, Simon Harrison, Chihunt Wong, Grant Goodman, Rin Nakamura, Voleak Choeurng, James Cooper, Suzanne Trudel

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

    Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients oleh Enrique M. Ocio, Sara Bringhen, Joaquin Martinez-Lopez, Jesus San-Miguel, Stefania Oliva, Paula Rodriguez-Otero, Nadia Le Roux, Yvonne Dong, Severine Doroumian, Sandrine Macé, Maria-Victoria Mateos

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

    PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACT... oleh Sagar Lonial, Hang Quach, Meletios A. Dimopoulos, Paula Rodríguez-Otero, Jesus Berdeja, Paul Richardson, Margee Kyada, Shuyu Chu, Min Chen, Patricia Abad, Juliane Morando, Niels W.C.J. van de Donk

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2

    689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2 oleh Lien Vandenberk, Paula Rodríguez-Otero, Maria-Victoria Mateos, Ajai Chari, Bhagirathbhai Dholaria, Deeksha Vishwamitra, Sheri Skerget, M Damiette Smit, Kalpana Bakshi, Sangmin Lee, Nizar Bahlis, Niels WCJ van de Donk, Raluca Verona

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULT... oleh Katja Weisel, Vania Hungria, Hang Quach, Sung-Soo Yoon, Paula Rodríguez-Otero, Glenn Kroog, Arijit Sinha, Anita Boyapati, Charlotte Lyon, Karen Rodriguez Lorenc, Timothy Inocencio, James Harnett, Lei Chi, Vygngley Moore, Peter Voorhees

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    <sup>11</sup>C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to <sup>18</sup>F-FDG PET/CT and Prognostic Value

    <sup>11</sup>C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to <sup>18</sup>F-FDG PET/CT and Prognostic Value oleh Maria I. Morales-Lozano, Paula Rodriguez-Otero, Lidia Sancho, Jorge M. Nuñez-Cordoba, Elena Prieto, Maria Marcos-Jubilar, Juan J. Rosales, Ana Alfonso, Edgar F. Guillen, Jesus San-Miguel, Maria J. Garcia-Velloso

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

    Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study oleh Michael H. Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J. Bahlis, Joaquin Martinez‐Lopez, Guenther Koehne, Paula Rodriguez‐Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T. Sullivan, Alexander M. Lesokhin

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma oleh Maria Victoria Mateos, Katja Weisel, Evangelos Terpos, Sossana Delimpasi, Efstathios Kastritis, Elena Zamagni, Michel Delforge, Enrique Ocio, Eirini Katodritou, Francesca Gay, Alessandra Larocca, Xavier Leleu, Paula Rodriguez Otero, Fredik Schjesvold, Michele Cavo, Meletios A. Dimopoulos

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma oleh Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Alicia Senin, Paula Rodriguez-Otero, Ray Powles, Kosei Matsue, Nina Shah, Larry D. Anderson, Matthew Streetly, Kimberly Wilson, Hoa Van Le, Arlene S. Swern, Amit Agarwal, David S. Siegel

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

    GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review oleh Paula Rodriguez-Otero, Niels W. C. J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar Bahlis, Ajai Chari

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS

    P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL)... oleh Michel Delforge, Krina Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas Marshall, Bertrand Arnulf, Michele Cavo, Ajay Nooka, Salomon Manier, Natalie Callander, Sergio Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa Mckiver, Mark Cook, Paula Rodríguez-Otero

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: